Pacritinib: Inhibitor of tyrosine-protein kinase JAK2 inhibitor of FLT-3 treatment of myelofibrosis

Drugs of the Future

Volumn 38, Issue 6, 2013, Pages 375-386

  Verstovsek, S ^a   Machida, C ^b   Dean, J P ^b   Myint, H ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Cell Therapeutics Inc   (United States)

Author keywords

Acute myeloid leukemia; Myelofibrosis; Pacritinib; SB 1518; Tyrosine protein kinase inhibitor

Indexed keywords

FLT3 LIGAND; JANUS KINASE 2; PACRITINIB; PROTEIN TYROSINE KINASE; STAT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL GROWTH; CELL LINE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; GASTROINTESTINAL TOXICITY; HUMAN; IC 50; MYELOFIBROSIS; MYELOID LEUKEMIA; MYELOPROLIFERATIVE NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; POLYCYTHEMIA; REVIEW; SINGLE DRUG DOSE;

EID: 84930541322     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2013.038.06.1964716     Document Type: Review

References (25)

1. William, A.D., Lee, A.C., Blanchard, S. et al. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza- tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21, 23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem 2011, 54(13): 4638-58.
2. Lee, A., William, A., Poulsen, A. et al. Design, synthesis and SAR studies leading to SB1518, a novel macrocyclic JAK2/FLT3 inhibitor in phase 2 clinical trials for myelofibrosis and lymphoma. 102nd Annu Meet Am Assoc Cancer Res (AACR) (April 2-6, Orlando) 2011, Abst 3564.
3. Blanchard, S., Lee, C.H.A., Nagaraj, H.K.M., Poulsen, A., Sun, E.T., Tan, Y.L.E., William, A.D. (S*BIO Pte. Ltd.). EP 1951729, JP 2009515954, US 8153632, WO 2007058627.
4. Tefferi, A., Barosi, G., Mesa, R.A. et al. International Working Croup (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006, 108(5): 1497-503. (Pubitemid 44316114)
5. Barosi, G. Emerging targeted therapies in myelofibrosis. Expert Rev Hematol 2012, 5(3): 313-24.
6. Cervantes, F., Dupriez, B., Pereira, A. et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113(13): 2895-901.
7. Geyer, H.L., Tibes, R., Mesa, R.A. et al. JAK2 inhibitors and their impact in myeloproliferative neoplasms. Hematology 2012, 17(1): S129-32.
8. Kralovics, R., Passamonti, F., Buser, A.S. et al. A gain of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352(17): 1779-90. (Pubitemid 40570926)
9. Shah, N.P., Olszynski, P., Sokol, L. et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 98.
10. Verstovsek, S., Mesa, R.A., Gotlib, J. et al. A double blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366(9): 799-807.
11. Harrison, C., Kiladjian, J., Al-Ali, H.K. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012, 366(9): 787-98.
12. Hart, S., Goh, K.C., Novotny-Diermayr, V. et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011, 25(11): 1751-9.
13. Goh, K.C., Hart, S., Tan, Y.C., Chithra, A., Ong, K.H., Wood, J. The effects of SB1518, a novel oral JAK2 inhibitor, on ex vivo expanded PV erythroid progenitors correlate with clinical observations. Blood [51st Annu Meet Am Soc Hematol (Dec 5-8, New Orleans) 2009] 2009, 114(22): Abst 2913.
14. Hart, S., Goh, K.C., Novotny-Diermayr, V. et al. Pacritinib (SR1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J 2011, 1(11): e44.
15. Verstovsek, S., Odenike, O., Scott, B. et al. Phase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis. Blood [51st Annu Meet Am Soc Hematol (Dec 5-8, New Orleans) 2009] 2009, 114(22): Abst 3905.
16. Younes, A., Romaguera, J., Fanale, M. et al Phase I study of a novel oral janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: Evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 2012, 30(33): 4161-7.
17. Tickenbrock, L., Muller-Tidow, C., Berdel,W.E., Serve, H. Emerging Flt3 kinase inhibitors in the treatment of leukemia. Expert Opin Emerg Drugs 2006, 11(1): 153-65.
18. Ikezoe, T., Kojima, S., Furihata, M. et al. Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. Int J Cancer 2011, 129(10): 2512-21.
19. Welsberg, E., Liu, E., Kung, A. et al. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: Synergism between FLT3 inhibitors, dasatinib/muiti-targeted inhibitors and JAK inhibitors. Leukemia 2012, 26(10): 2233-44.
20. Steensma, D.P., McClure, R.F., Karp, J.E. et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006, 20(6): 971-8. (Pubitemid 43797287)
21. Harry, B.L., Eckhardt, G., Jimeno, A. JAK2 inhibition for the treatment of hematologic and solid malignancies. Expert Opin Investig Drugs 2012, 21(5): 637-55.
22. McFarland, B.C., Ma, J.Y., Langford, C.P. et al. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther 2011, 10(12): 2384-93.
23. Liu, H., Tekle, C., Chen, Y.W. et al. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther 2011, 10(6): 960-71.
24. Tefferi, A., Vardiman, J.W. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008, 22(1): 14-22.
25. Cheson, B.D., Pfistner, B., Juweid, M.E. et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25(5): 579-86. (Pubitemid 350002966)